That scenario plays out in infectious disease practices every week, and it traces back to one decision made long before the patient walked in: was this medication routed through white bagging or buy-and-bill?
Independent ID practices running OPAT programs, infusion suites, or hospital outpatient administration often juggle both models at once — sometimes without a written policy for either. The model determines who buys the drug, who absorbs the financial risk if something goes wrong, and how fast a patient actually starts treatment.
This article breaks down both procurement paths, where each one creates friction for infectious disease care specifically, and how to decide which one fits a given payer, drug, and clinical situation — not as a universal rule, but as a practice-specific calculation.
Key Takeaways
- White bagging routes the drug through a payer-designated specialty pharmacy; buy-and-bill requires the practice to purchase, store, and bill for it directly
- Inventory exposure drops under white bagging, but delivery, authorization, and scheduling fall outside the practice's control
- Buy-and-bill gives practices more control over timing but exposes them to acquisition cost, wastage, and denial risk
- Payer and drug-specific sourcing rules should be confirmed in writing before a treatment plan is built
- Compare models using the practice's own acquisition cost, denial history, and cash-flow data, not generic industry figures
White Bagging vs Buy-and-Bill: Quick Comparison
Both models get a drug into a patient's arm. How they get there, and who's financially exposed along the way, looks nothing alike.
Drug Sourcing and Ownership
In white bagging, a payer-designated or payer-approved specialty pharmacy dispenses the medication for a specific patient and ships it to the administration site. The practice administers the dose but never purchases or bills for the drug itself.
In buy-and-bill, the practice purchases the medication through its own authorized channel (typically a distributor) and holds custody from receipt through administration. It bills the payer for both the drug and the administration service.
Inventory and Financial Exposure
- White bagging: No acquisition cost or spread for the practice; risk shifts to unusable shipments, delivery failures, and schedule changes the practice didn't cause
- Buy-and-bill: The practice funds inventory before payment arrives, absorbs wastage, and carries the gap between acquisition cost and payer reimbursement
Site of Service and Scheduling
White-bagged administration depends on the specialty pharmacy receiving the order, clearing authorization, and delivering product to the correct site before the appointment. Miss any link in that chain, and the appointment slips.
Buy-and-bill inventory sits on-site, which generally supports more flexible scheduling when the practice has the authorization, storage, and working capital to back it up.
Billing and Reimbursement
Under buy-and-bill, the practice bills for both the drug and administration, reconciling acquisition records, NDC codes, and wastage reporting against payer-specific rules.
Under white bagging, the specialty pharmacy typically bills the drug claim; the practice bills administration only. UnitedHealthcare's 2025 commercial sourcing protocol states that providers may bill the administration code but may not bill the payer or member for the supplied medication itself.
Operational and Patient-Access Risk
Shipment timing, cold-chain handling, and multi-party coordination (prescriber, payer, pharmacy, facility, patient) drive white-bagging risk. Purchasing lead times, storage capacity, and cash-flow exposure drive buy-and-bill risk. Neither risk profile disappears; it just lands on a different party.
What Is White Bagging?
White bagging is a payer-directed arrangement: a specialty pharmacy dispenses a medication for a named patient and ships it directly to the site where a clinician will administer it. This differs from brown bagging, where the patient personally picks up the drug and transports it to the appointment. Confirm that distinction with each payer, since the rules and risks differ.
The Typical Workflow
- Benefits investigation confirms whether the plan requires specialty-pharmacy sourcing for that specific drug
- Prior authorization is submitted and tracked against a clock that should start at referral, not at first submission
- Specialty pharmacy dispenses and ships the patient-specific product to the administration site
- Receipt, storage, and administration happen on the clinical side, with documentation coordinated across both parties
- Claims are split: the pharmacy bills the drug, the practice bills administration
Potential Benefits and Real Burdens
For an independent ID practice, white bagging can mean less provider-funded inventory and reduced exposure to carrying large quantities of expensive biologics. That's a genuine operational relief, but it comes with trade-offs:
- Multiple handoffs between prescriber, pharmacy, payer, and facility
- Shipment delays or incorrect delivery locations (ASHP has documented cases of doses shipped to a patient's home instead of the intended clinic)
- Cold-chain and storage mismatches between what the pharmacy ships and what the site can handle
- Uncertainty over who replaces a dose that's damaged, lost, or arrives unusable
Where It Gets Disruptive in ID Care
White bagging tends to work reasonably well for predictable, scheduled infusions with stable dosing. It gets much harder with:
- Urgent treatment starts, where waiting on specialty-pharmacy fulfillment delays care
- Frequent dose changes mid-course, since each change may require a new dispense cycle
- Unstable patients needing same-day adjustments based on labs or clinical status
OPAT courses that depend on weekly reassessment are particularly exposed here, since a dose change can trigger a fresh authorization-to-delivery cycle before the next infusion.
Important: sourcing requirements vary by payer, drug, and state. IDSA's 2018 OPAT guideline notes that payer factors, patient resources, and support structure all shape which delivery setting is feasible. There's no single rule that applies across plans or medications.
What Is Buy-and-Bill?
Buy-and-bill is the provider-acquisition model: the practice purchases the drug, takes custody of it, administers it, and bills the payer for both the drug and the administration service.
The Operational Sequence
The order matters here. Reversing any two steps creates financial exposure:
- Verify coverage and obtain authorization before committing capital
- Acquire the drug through an authorized purchasing channel
- Receive and verify lot numbers and expiration dates
- Store correctly, with temperature monitoring and documented backup power
- Administer and document the dose, including any discarded quantity
- Bill with supporting records matching what was purchased and administered
Advantages and the Costs That Come With Them
Buy-and-bill gives practices real control: medication is on-site, scheduling isn't dependent on a courier, and urgent starts or dose changes don't require waiting on a third party. That control has a price:
- Acquisition cost funded before reimbursement arrives
- Inventory days that tie up working capital
- Wastage from unused or expired product
- Denial risk: a hard denial on a drug already administered is a realized loss, not a delayed payment
For most separately payable Part B drugs, CMS's Part B Drugs page confirms Medicare pays based on average sales price plus 6%, with administration paid separately. That spread between acquisition cost and ASP-based payment is practice-specific, drug-specific, and time-specific. There's no general margin figure that applies across the board.
Controls That Keep This Model Safe
- Secure, monitored storage with a tested backup plan, not an assumed one
- Monthly reconciliation of administered doses against inventory; unexplained gaps are either uncosted wastage or uncaptured charges
- Correct reporting of discarded drug quantities, since billing-unit rules determine when that's even reportable
- A one-page reference per drug per payer covering required criteria, channel, and turnaround time
- Loaded fee schedules to catch underpayment, since a drug claim paid below contract typically triggers no rejection or alert on its own
White Bagging vs Buy-and-Bill: What Is Better?
Neither model wins universally. The right answer depends on a worksheet, not a preference.
Build the Comparison Around These Factors
- Whether the payer mandates one model for the specific drug
- Drug acquisition cost versus expected reimbursement
- Authorization turnaround time and treatment urgency
- Dose predictability and how often it changes mid-course
- Storage capacity, inventory turnover, and wastage exposure
- Denial history and the practice's cash-flow tolerance
Choose white bagging when the payer requires or strongly favors specialty-pharmacy fulfillment, the treatment schedule is predictable, and the delivery process has proven reliable. Choose buy-and-bill when the payer permits provider acquisition, dose changes make patient-specific shipment impractical, and the practice can safely finance and store inventory.
Here's the catch: when white bagging is payer-mandated, it isn't really a choice. The real task becomes building a reliable exception, escalation, and patient-notification process for when the pharmacy shipment doesn't arrive on time.
A Quick Scenario Comparison
A patient on a stable, six-week scheduled infusion with no anticipated dose changes is a reasonable fit for white bagging — the predictability limits the coordination risk. A patient starting urgent OPAT therapy with weekly dose adjustments based on labs is a poor fit; buy-and-bill (where permitted) avoids the authorization-to-delivery lag that a dose change would otherwise trigger.
Pre-Implementation Checklist
- Confirm the payer's policy in writing for each relevant drug
- Identify the responsible specialty pharmacy and its escalation contact
- Verify delivery, tracking, and replacement procedures before the first shipment
- Define scheduling checkpoints tied to confirmed delivery, not assumed delivery
- Assign staff ownership for each handoff
- Track delays, denials, wastage, and unreimbursed cost as ongoing metrics
Running these numbers requires the practice's own acquisition costs, denial history, and staffing data — not generic benchmarks. GrowInfectiousDisease's free, browser-based Infusion & OPAT Economics Calculator lets practices model drug acquisition, nursing time, and reimbursement across a full therapy course using their own figures; nothing entered is transmitted or stored. It's an educational tool, not a substitute for payer, legal, pharmacy, or clinical guidance.
Conclusion
White bagging and buy-and-bill are different medication-supply and reimbursement workflows, not competing philosophies. One isn't automatically better for every infectious disease drug, payer, or site of care.
Practices that handle this well treat it as a recurring verification task:
- Confirm the plan's sourcing rules before the treatment plan is finalized
- Run the numbers using the practice's own cost and denial data
- Build the handoff process that protects timely treatment without putting cash flow or inventory at unmanaged risk
Frequently Asked Questions
What is a medical billing audit?
A medical billing audit is a structured review of claims, coding, documentation, payments, denials, and compliance. For infectious disease practices, it can surface issues in drug and administration billing, but it doesn't determine whether white bagging or buy-and-bill applies.
What does a medical billing auditor do?
An auditor reviews medical records, claims, payer rules, coding accuracy, and workflow controls. ID practices often use this review to examine drug billing, administration claims, denials, and supporting documentation.
Who audits hospital billing?
Audits can come from internal compliance or revenue-cycle teams, external billing auditors, commercial payers, Medicare contractors, or Medicaid agencies. A practice-initiated audit is different from a payer or government-initiated review.
What triggers a CMS audit?
CMS reviews may be prompted by data anomalies, unusual billing patterns, documentation concerns, or targeted compliance enforcement. There's no fixed trigger list. Check current CMS guidance for the latest criteria.
What to say to lower a hospital bill?
Request an itemized bill, compare it against the explanation of benefits, and ask about errors or duplicate charges. Also ask about payment-assistance programs or appeal options. This is separate from the white bagging versus buy-and-bill decision.
